Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON34689
NL-OMON34689
Completed
Not Applicable

The value of biomarkers in cerebrospinal fluid in acute spinal cord injury as predictor of outcome. - SPinal cord Diagnostic Improvements (SPIDI) study

niversitair Medisch Centrum Sint Radboud0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsspinal cord injurytraumatic myelopathy10041543

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
spinal cord injury
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
30
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • •Blunt spinal cord injury (Neurological level of injury C2\-Th10\)
  • •Neurological deficit
  • •Primarily refererred
  • •Glasgow Coma Scale \>\= 10 (E4\+V6\)

Exclusion Criteria

  • •penetrating spinal cord injury
  • •normal neurologic examination
  • •non\-traumatic spinal cord injury
  • •traumatic brain injury
  • •pre\-existent neurological disorder

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Cerebrospinal fluid metabolites as marker for the severity of progressive post-hemorrhagic ventricular dilatation in preterm infants
NL-OMON30135niversitair Medisch Centrum Sint Radboud125
Completed
Not Applicable
Identification of Biomarkers in Spinocerebellar Ataxia 3Spinocerebellar Ataxia Type 3
NCT03885167University of Michigan22
Recruiting
Not Applicable
Identification of a CSF- and blood biomarker fingerprint differentiating between highly active and moderate/mild forms of multiple sclerosis (MS)G35Multiple sclerosis
DRKS00015761Klinikum der Johann Wolfgang Goethe-UniversitätZentrum der Neurologie und Neurochirurgie200
Not yet recruiting
Not Applicable
Hersenvocht bij psychiatrische aandoeningePsychosis, schizophrenia, affective disorders, depression
NL-OMON26758niversity Medical Center Utrecht800
Active, not recruiting
Phase 2
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionGaucher Disease Type 1Gaucher Disease Type 3
NCT02843035Genzyme, a Sanofi Company12